Certara Under Investigation, Shares Plunge 19%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 42 minutes ago
0mins
Source: Globenewswire
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Certara, focusing on potential violations of securities laws related to false or misleading statements that may affect investor rights.
- Decline in Financial Performance: Certara reported a drop in service revenues and bookings in its Q1 2026 financial results, attributing this decline to softer performance from Tier 1 customers in MIDD services, indicating weakened market demand.
- Stock Price Volatility: Following the disappointing earnings report, Certara's shares plummeted by 19% on the same day, reflecting investor concerns about the company's future prospects and a loss of market confidence.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's proactive stance in safeguarding investor interests, which may lead to further legal actions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CERT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CERT
Wall Street analysts forecast CERT stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 5.170
Low
9.00
Averages
12.11
High
16.00
Current: 5.170
Low
9.00
Averages
12.11
High
16.00
About CERT
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Certara Under Investigation, Shares Plunge 19%
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Certara, focusing on potential violations of securities laws related to false or misleading statements that may affect investor rights.
- Decline in Financial Performance: Certara reported a drop in service revenues and bookings in its Q1 2026 financial results, attributing this decline to softer performance from Tier 1 customers in MIDD services, indicating weakened market demand.
- Stock Price Volatility: Following the disappointing earnings report, Certara's shares plummeted by 19% on the same day, reflecting investor concerns about the company's future prospects and a loss of market confidence.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's proactive stance in safeguarding investor interests, which may lead to further legal actions.
See More
Certara Under Investigation for Possible Securities Violations
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in Q1 2026, indicating weakened customer demand that could hinder future revenue growth.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance, suggesting that market demand uncertainty may negatively impact Certara's business strategy moving forward.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a decision that could further affect its revenue streams, especially in the current market environment, potentially leading to customer attrition and revenue decline.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price fell from $6.31 per share on May 8 to $5.13 per share on May 11, a decline of approximately 19%, reflecting investor concerns about the company's future outlook.
See More
Certara Under Investigation for Securities Fraud Claims
- Declining Financial Performance: Certara's Q1 2026 report revealed a 4% year-over-year decline in service revenue to $57.2 million, alongside a 14% drop in service bookings to $66.6 million, indicating weakened customer demand that could hinder future revenue growth.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance, which may erode investor confidence in the company's future prospects and negatively impact stock performance.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a strategic shift that could affect its market positioning and revenue streams, particularly as demand for regulatory services continues to rise.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price fell by $1.18, approximately 19%, closing at $5.13, reflecting market concerns over the company's financial health and potentially prompting investors to reassess their investment strategies.
See More
Certara Faces Securities Investigation as Shares Plunge 19%
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, indicating weakened competitiveness in the market.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance reflecting instability in market demand, which could adversely affect future revenue growth.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a strategic shift that may further impact the company's revenue structure and market positioning, increasing future uncertainties.
- Stock Price Volatility: Following the earnings report, Certara's stock price plummeted from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, indicating investor concerns about the company's outlook and a drop in market confidence.
See More
Certara to Participate in Multiple Investor Conferences
- Investor Conference Schedule: Certara will participate in the RBC CM Global Healthcare Conference on May 19 at 9:30 a.m. ET, showcasing its leadership in drug development and attracting investor interest.
- Subsequent Conference Dates: The company will also attend William Blair's 46th Annual Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 3, further expanding its market presence.
- Webcast Availability: Live webcasts for the RBC and Jefferies conferences will be available on Certara's investor relations website and will be accessible for replay for at least 90 days thereafter, ensuring timely information access for investors.
- Company Background: Certara is a global leader in model-informed drug development, serving over 2,600 biopharmaceutical companies and regulatory agencies across 70 countries, highlighting its extensive influence in the industry.
See More
Investigation Launched into Certara by Law Firm for Investor Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in service revenue to $57.2 million and a 14% drop in service bookings to $66.6 million in its Q1 2026 results, indicating significant challenges in customer demand that could impact future revenue growth.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, describing overall service performance as 'mixed', which may lead to decreased investor confidence in the company's future performance and negatively affect its stock price.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its services segment, a strategic shift that could further impact the company's revenue structure and raise concerns among investors regarding its long-term strategy.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price fell from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, reflecting the market's negative reaction to the company's financial health and potentially prompting more investors to seek legal recourse to protect their interests.
See More
Certara Under Investigation, Shares Plunge 19%
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Certara, focusing on potential violations of securities laws related to false or misleading statements that may affect investor rights.
- Decline in Financial Performance: Certara reported a drop in service revenues and bookings in its Q1 2026 financial results, attributing this decline to softer performance from Tier 1 customers in MIDD services, indicating weakened market demand.
- Stock Price Volatility: Following the disappointing earnings report, Certara's shares plummeted by 19% on the same day, reflecting investor concerns about the company's future prospects and a loss of market confidence.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's proactive stance in safeguarding investor interests, which may lead to further legal actions.
See More
Certara Under Investigation for Possible Securities Violations
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in Q1 2026, indicating weakened customer demand that could hinder future revenue growth.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance, suggesting that market demand uncertainty may negatively impact Certara's business strategy moving forward.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a decision that could further affect its revenue streams, especially in the current market environment, potentially leading to customer attrition and revenue decline.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price fell from $6.31 per share on May 8 to $5.13 per share on May 11, a decline of approximately 19%, reflecting investor concerns about the company's future outlook.
See More
Certara Under Investigation for Securities Fraud Claims
- Declining Financial Performance: Certara's Q1 2026 report revealed a 4% year-over-year decline in service revenue to $57.2 million, alongside a 14% drop in service bookings to $66.6 million, indicating weakened customer demand that could hinder future revenue growth.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance, which may erode investor confidence in the company's future prospects and negatively impact stock performance.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a strategic shift that could affect its market positioning and revenue streams, particularly as demand for regulatory services continues to rise.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price fell by $1.18, approximately 19%, closing at $5.13, reflecting market concerns over the company's financial health and potentially prompting investors to reassess their investment strategies.
See More
Certara Faces Securities Investigation as Shares Plunge 19%
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, indicating weakened competitiveness in the market.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance reflecting instability in market demand, which could adversely affect future revenue growth.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a strategic shift that may further impact the company's revenue structure and market positioning, increasing future uncertainties.
- Stock Price Volatility: Following the earnings report, Certara's stock price plummeted from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, indicating investor concerns about the company's outlook and a drop in market confidence.
See More
Certara to Participate in Multiple Investor Conferences
- Investor Conference Schedule: Certara will participate in the RBC CM Global Healthcare Conference on May 19 at 9:30 a.m. ET, showcasing its leadership in drug development and attracting investor interest.
- Subsequent Conference Dates: The company will also attend William Blair's 46th Annual Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 3, further expanding its market presence.
- Webcast Availability: Live webcasts for the RBC and Jefferies conferences will be available on Certara's investor relations website and will be accessible for replay for at least 90 days thereafter, ensuring timely information access for investors.
- Company Background: Certara is a global leader in model-informed drug development, serving over 2,600 biopharmaceutical companies and regulatory agencies across 70 countries, highlighting its extensive influence in the industry.
See More
Investigation Launched into Certara by Law Firm for Investor Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in service revenue to $57.2 million and a 14% drop in service bookings to $66.6 million in its Q1 2026 results, indicating significant challenges in customer demand that could impact future revenue growth.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, describing overall service performance as 'mixed', which may lead to decreased investor confidence in the company's future performance and negatively affect its stock price.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its services segment, a strategic shift that could further impact the company's revenue structure and raise concerns among investors regarding its long-term strategy.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price fell from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, reflecting the market's negative reaction to the company's financial health and potentially prompting more investors to seek legal recourse to protect their interests.
See More
